OptimizeRx (NASDAQ:OPRX) Releases Quarterly Earnings Results, Misses Expectations By $0.11 EPS

OptimizeRx (NASDAQ:OPRX) announced its quarterly earnings data on Wednesday. The company reported $0.14 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.25 by ($0.11), Zacks reports. OptimizeRx had a negative return on equity of 4.92% and a negative net margin of 27.41%. OptimizeRx updated its FY 2025 guidance to EPS.

OptimizeRx Stock Up 38.1 %

NASDAQ:OPRX traded up $1.58 during mid-day trading on Wednesday, hitting $5.72. 8,961,628 shares of the company’s stock traded hands, compared to its average volume of 211,006. The company has a fifty day moving average of $5.41 and a 200 day moving average of $5.92. The company has a debt-to-equity ratio of 0.29, a quick ratio of 3.23 and a current ratio of 3.23. OptimizeRx has a twelve month low of $3.78 and a twelve month high of $14.80. The company has a market capitalization of $105.35 million, a P/E ratio of -4.17 and a beta of 1.31.

Analyst Ratings Changes

A number of research analysts have commented on OPRX shares. William Blair reissued an “outperform” rating on shares of OptimizeRx in a research report on Thursday, November 14th. B. Riley cut their price objective on shares of OptimizeRx from $17.00 to $13.00 and set a “buy” rating on the stock in a report on Tuesday, December 24th. Stephens started coverage on OptimizeRx in a report on Friday, December 20th. They set an “equal weight” rating and a $5.50 target price for the company. Royal Bank of Canada reiterated a “sector perform” rating and issued a $6.00 price target (down from $7.00) on shares of OptimizeRx in a report on Wednesday, January 8th. Finally, Roth Mkm reissued a “buy” rating and issued a $16.00 price target (down from $20.00) on shares of OptimizeRx in a research report on Thursday, November 14th. Three investment analysts have rated the stock with a hold rating and six have given a buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $9.06.

Insider Transactions at OptimizeRx

In other news, CEO William J. Febbo purchased 20,000 shares of the stock in a transaction on Thursday, December 12th. The stock was bought at an average price of $5.01 per share, with a total value of $100,200.00. Following the transaction, the chief executive officer now owns 601,253 shares in the company, valued at $3,012,277.53. The trade was a 3.44 % increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 6.10% of the company’s stock.

OptimizeRx Company Profile

OptimizeRx Corporation, a digital health technology company, enables care-focused engagement between life sciences organizations, healthcare providers, and patients at critical junctures throughout the patient care journey. It offers various tech-enabled marketing solutions through its Artificial Intelligence-generated Dynamic Audience and Activation Platform, which enables customers to execute traditional marketing campaigns on its proprietary digital point-of-care network, as well as dynamic marketing campaigns that optimize audiences in real time to increase the value of treatment information for healthcare professionals and patients in response to clinical care events.